Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Operations (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash from Operations for 6 consecutive years, with 17233000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 19.81% to 17233000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67851000.0 through Dec 2025, up 62.05% year-over-year, with the annual reading at 67851000.0 for FY2025, 62.05% up from the prior year.
  • Cash from Operations for Q4 2025 was 17233000.0 at Lexicon Pharmaceuticals, up from 23833000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 16993000.0 in Q2 2025, with the low at 55130000.0 in Q1 2024.
  • Average Cash from Operations over 3 years is 34044000.0, with a median of 39868000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations plummeted 74.39% in 2024, then skyrocketed 135.01% in 2025.
  • Over 3 years, Cash from Operations stood at 50548000.0 in 2023, then skyrocketed by 57.48% to 21491000.0 in 2024, then increased by 19.81% to 17233000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 17233000.0, 23833000.0, and 16993000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.